Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-prevention

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2014 Jun 26

PMID 24962285

Citations 26

Authors

M-J Milloy

Julio S G Montaner

Evan Wood

Affiliations

Soon will be listed here.

Abstract

Contact with the criminal justice system, including incarceration, is a common experience for many people living with HIV/AIDS. Optimism has recently been expressed that correctional facilities could be important locations for treatment-as-prevention (TasP)-based initiatives. We review recent findings regarding the effect of incarceration on patterns of HIV transmission, testing, treatment initiation and retention. We found that the prevalence of HIV infection among incarcerated individuals remains higher than analogous non-incarcerated populations. Recent studies have shown that voluntary HIV/AIDS testing is feasible in many correctional facilities, although the number of previously undiagnosed individuals identified has been modest. Studies have implied enhanced linkage to HIV/AIDS treatment and care in jails in the United States was associated with improvements in the HIV cascade of care. However, for many individuals living with HIV/AIDS, exposure to the correctional system remains an important barrier to retention in HIV/AIDS treatment and care. Future research should evaluate structural interventions to address these barriers and facilitate the scale-up of TasP-based efforts among individuals living in correctional settings.

Citing Articles

Odds of HIV among incarcerated drug users: a systematic review and meta-analysis of Asian countries.

Ul Hussain H, Ashok Kumar K, Tayyaba Rehan S, Khan Z, Hashmi M, Khabir Y Ann Med Surg (Lond). 2023; 85(11):5584-5592.

PMID: 37915701 PMC: 10617921. DOI: 10.1097/MS9.0000000000001242.

Implementing Preexposure Prophylaxis for HIV Prevention in a Statewide Correctional System in the United States.

Murphy M, Rogers B, Ames E, Galipeau D, Uber J, Napoleon S Public Health Rep. 2023; 139(2):174-179.

PMID: 37476929 PMC: 10851896. DOI: 10.1177/00333549231186576.

We the People: A Black Strategy to End the HIV Epidemic in the United States of America.

Lewis T, Boykin M J Healthc Sci Humanit. 2023; 11(1):173-192.

PMID: 36818216 PMC: 9930506.

Self-Reported Adherence to Antiretroviral Therapy (ART) Among Women Engaged in Commercial Sex Work in Southern Uganda.

Kiyingi J, Nabunya P, Kizito S, Nabayinda J, Nsubuga E, Bahar O AIDS Behav. 2022; 27(3):1004-1012.

PMID: 36066764 PMC: 9974600. DOI: 10.1007/s10461-022-03837-9.

HIV and Incarceration: Implications for HIV-Positive People Who Use Illicit Drugs During a Seek, Test, Treat, and Retain Initiative in Canada.

Blumenkrans E, Hamilton J, Mohd Salleh N, Kaida A, Small W, Barrios R J Correct Health Care. 2022; 28(4):236-242.

PMID: 35758827 PMC: 9529366. DOI: 10.1089/jchc.20.04.0021.

References

Cescon A, Kanters S, Brumme C, Lepik K, Forrest J, Hull M . Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010. J Acquir Immune Defic Syndr. 2013; 65(1):107-14. PMC: 4266465. DOI: 10.1097/QAI.0b013e3182a8efc3. View

Branson B, Viall A, Marum E . Expanding HIV testing: back to the future. J Acquir Immune Defic Syndr. 2013; 63 Suppl 2:S117-21. DOI: 10.1097/QAI.0b013e3182986f25. View

Milloy M, Kerr T, Bangsberg D, Buxton J, Parashar S, Guillemi S . Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS. 2011; 26(1):60-7. PMC: 3242618. DOI: 10.1089/apc.2011.0169. View

Baillargeon J, Giordano T, Rich J, Wu Z, Wells K, Pollock B . Accessing antiretroviral therapy following release from prison. JAMA. 2009; 301(8):848-57. PMC: 2936238. DOI: 10.1001/jama.2009.202. View

Rich J, Dickinson B, Macalino G, Flanigan T, Towe C, Spaulding A . Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. J Acquir Immune Defic Syndr. 2000; 22(2):161-6. DOI: 10.1097/00126334-199910010-00008. View

Milloy M, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S . Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2011; 59(4):393-9. PMC: 3299888. DOI: 10.1097/QAI.0b013e3182433288. View

Mohamed H, Saad Z, Abd-Elreheem E, Abd-ElGhany W, Mohamed M, Elnaeem E . Hepatitis C, hepatitis B and HIV infection among Egyptian prisoners: seroprevalence, risk factors and related chronic liver diseases. J Infect Public Health. 2013; 6(3):186-95. DOI: 10.1016/j.jiph.2012.12.003. View

Izenberg J, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice F . High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013; 133(1):154-60. PMC: 3786010. DOI: 10.1016/j.drugalcdep.2013.05.018. View

Dolan K, Wodak A . HIV transmission in a prison system in an Australian State. Med J Aust. 1999; 171(1):14-7. DOI: 10.5694/j.1326-5377.1999.tb123490.x. View

10.

Milloy M, Montaner J, Wood E . Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'. Curr Opin HIV AIDS. 2012; 7(4):332-8. DOI: 10.1097/COH.0b013e328354bcc8. View

11.

Spaulding A, Booker C, Freeman S, Ball S, Stein M, Jordan A . Jails, HIV testing, and linkage to care services: an overview of the EnhanceLink initiative. AIDS Behav. 2012; 17 Suppl 2:S100-7. DOI: 10.1007/s10461-012-0339-2. View

12.

Jurgens R, Nowak M, Day M . HIV and incarceration: prisons and detention. J Int AIDS Soc. 2011; 14:26. PMC: 3123257. DOI: 10.1186/1758-2652-14-26. View

13.

Althoff A, Zelenev A, Meyer J, Fu J, Brown S, Vagenas P . Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2012; 17 Suppl 2:S156-70. PMC: 3714328. DOI: 10.1007/s10461-012-0372-1. View

14.

Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H . Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000; 34(5):431-6. DOI: 10.1590/s0034-89102000000500001. View

15.

Widman L, Noar S, Golin C, Willoughby J, Crosby R . Incarceration and unstable housing interact to predict sexual risk behaviours among African American STD clinic patients. Int J STD AIDS. 2013; 25(5):348-54. PMC: 4037926. DOI: 10.1177/0956462413505999. View

16.

Rotily M, Weilandt C, Bird S, Kall K, Van Haastrecht H, Iandolo E . Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Public Health. 2001; 11(3):243-50. DOI: 10.1093/eurpub/11.3.243. View

17.

Chitsaz E, Meyer J, Krishnan A, Springer S, Marcus R, Zaller N . Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav. 2013; 17 Suppl 2:S118-27. PMC: 3818019. DOI: 10.1007/s10461-013-0506-0. View

18.

Wohl D, Golin C, Rosen D, May J, White B . Detection of undiagnosed HIV among state prison entrants. JAMA. 2013; 310(20):2198-9. PMC: 4329507. DOI: 10.1001/jama.2013.280740. View

19.

Jurgens R, Betteridge G . Prisoners who inject drugs: public health and human rights imperatives. Health Hum Rights. 2006; 8(2):46-74. View

20.

Menezes P, Rosen D, Wohl D, Kiziah N, Sebastian J, Eron Jr J . Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. AIDS Res Hum Retroviruses. 2012; 29(1):136-41. PMC: 3537299. DOI: 10.1089/AID.2012.0102. View